Carregant...

Adverse Events of Trastuzumab Emtansine (T-DM1) in the Treatment of HER2-Positive Breast Cancer Patients

The human epidermal growth factor receptor 2 (HER2) is commonly associated with poor prognosis and is overexpressed in approximately 15–20% of all breast cancers. The introduction of HER2-targeted therapies led to significant improvement in the prognosis of patients with HER2-positive breast cancer,...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Breast Care (Basel)
Autors principals: Kowalczyk, Lidia, Bartsch, Rupert, Singer, Christian F., Farr, Alex
Format: Artigo
Idioma:Inglês
Publicat: S. Karger GmbH 2017
Matèries:
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5803744/
https://ncbi.nlm.nih.gov/pubmed/29456473
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1159/000480492
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!